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INTRODUCTION
Asthma is a chronic disorder that can place considerable
restrictions on the physical, emotional, and social aspects of
the lives of patients and may have an impact on their careers.
Many people with asthma do not completely appreciate the
impact of the disease on their social life and claim the lead
“normal” lives either because normality may be based on
adjustments and restrictions that they have already incorpo-
rated into their lifestyle or because they deny their restriction,
wanting to “live like others” (1). Recently studies of patient
outcomes in asthma have focused on clinical and physiologic
measures (2). Although such clinical measures do not provide
a complete, accurate view of the impact of a disease on an
individual’s physical, social, or emotional well being, health
related quality of life measures are increasingly being inte-
grated into clinical research in asthma (2-4). 
Inhaled glucocorticoids (GCs) have revolutionized the treat-
ment of asthma and have now become the mainstay of therapy
for patients with chronic asthma (5, 6). Asthma management
guidelines (1) have mentioned that the early intervention and
effective dosage (start high-go low), and enough period of
inhaled GCs would be the best way to control and maintain
asthma symptoms. Control of asthma (1) is monitored by asth-
ma symptoms, the use of rescue inhaled  2-agonist, and mea-
surement of diurnal variation of peak expiratory flow (PEF),
FEV1, and by non-invasive markers of inflammation such as
exhaled nitric oxide and induced sputum and airway hyper-
responsiveness. A wide variation of response to inhaled GCs is
expected between patients, but there is little data about respon-
siveness to high dose inhaled GCs relation to change in FEV1
and asthma symptoms such as asthma quality of life question-
naire (AQLQ). Therefore, the aims of this study were to exam-
ine the effect of  maximally recommended dose of inhaled GCs
(1,000  g of fluticasone propionate, FP) for 4 wks on AQLQ
of patients with moderate to severe asthma, and the correlation
of AQLQ with asthma severity and GCs responsiveness. 
MATERIALS AND METHODS
Study design
On the first day of study, a clinical history was obtained
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Effect of High Dose Inhaled Glucocorticoids on Quality of Life in
Patients with Moderate to Severe Asthma
Asthma is a chronic disorder that can place considerable restrictions on the physi-
cal, emotional, and social aspects of the lives of patients. Inhaled glucocorticoids
(GCs) are the most effective controller therapy. The purpose of this study was to
evaluate the effect of inhaled GCs on quality of life in patients with moderate to
severe asthma. Patients completed the asthma quality of life questionnaire (AQLQ)
and pulmonary function test at baseline and after 4 wks treatment of GCs. We
enrolled 60 patients who had reversibility in FEV1 after 200  g of albuterol of 15%
or more and/or positive methacholine provocation test, and initial FEV1% predicted
less than 80%. All patients received inhaled GCs (fluticasone propionate 1,000  g/
day) for 4 wks. The score of AQLQ was significantly improved following inhaled
GCs (overall 51.9±14.3 vs. 67.5±12.1, p<0.05). The change from day 1 to day
28 in FEV1 following inhaled GCs was diversely ranged from -21.0% to 126.8%.
The improvement of score of AQLQ was not different between at baseline and
after treatment of GCs according to asthma severity and GCs responsiveness.
Quality of life was improved after inhaled GCs regardless of asthma severity and
GCs responsiveness in patients with moderate to severe asthma.
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using a physician-administered questionnaire. Chest PA radio-
graphy, the allergy skin prick test, and spirometry including
bronchodilator response after inhalation of 2 puffs of 100  g
aerosolized albuterol were performed. Blood and sputum were
sampled for differential cell counts. AQLQ was evaluated at
baseline and 4 wks. On second day, airway hyperrespousive-
ness (AHR) was measured in case of 70% or more in FEV1%
predicted. The patients were educated visually by the trained
nurse how to use the inhaled GCs until the accuracy score
reach 12 of 14 (maximal score) (7). The inhaled GCs was
started and maintained for 4 wks. The dose of inhaled GCs
used via a multi-dose dry powder inhaler was FP 1,000  g/
day (2 puff b.i.d, Diskhaler; GSK, U.S.A.). During the study
period, the patients were asked to record their symptom score
and medication usage. The patients used short acting bron-
chodilator as needed base. The switch to combination or add
on therapy was done in exacerbation during study period;
deterioration of greater than 12% in AQLQ or FEV1 at any
time with developing aggravating symptoms. The primary
end points were the change in AQLQ, basal FEV1, FEF25-75%,
and FEV1/FVC after treatment of inhaled GCs.
Subjects
The patients with chronic asthma were recruited from the
out patient clinics in Soonchunhyang University Hospital.
All patients with asthma had currently  one or more asthma
symptoms and the findings of physical examination compati-
ble with asthma definition by the American Thoracic Society
(8). Each patient showed airway reversibility as documented
by a positive bronchodilator response of more than 15% in-
crease in FEV1 and/or an airway hyper-reactivity of less than
10 mg/mL methacholine (9). Asthma severity was classified
with symptoms, pulmonary function before treatment. The
exclusion criteria were as follows: duration of asthma less than
one year, acute exacerbated asthma within 4 wks, history of
brittle asthma, atopic individuals to pollens, parenchymal
lung diseases on chest radiography, diffusing capacity less than
80%, previous inhaled steroid or systemic steroid usage with-
in the past 4 wks, and maintaining theophylline or leukotriene
antagonist therapy. The prospective controlled trial involved
60 patients of mean age 45 yr with moderate to severe per-
sistent asthma. The clinical parameters are summarized in
Table 1. 42.5% of asthmatics showed positive skin test to
the common inhalant allergens. The change from day 1 to
day 28 in FEV1 [ FEV1=(FEV1 at 4 wks-baseline FEV1)/
baseline FEV1] following inhaled GCs was measured. Respon-
der to inhaled GCs was regarded as demonstrating greater
response than 12% or more in  FEV1. During this period,
5 patients of asthmatics moved to the combination or add on
therapy according to the protocol due to decreases of greater
than 12% in FEV1 or AQLQ with symptom aggravation.
This study was performed with the approval of the Ethics
Committee of the University Hospital and informed writ-
ten consent was obtained from all study subjects. 
Quality of life measurement
AQLQ was evaluated at baseline and 4 wks by using the
quality of life questionnaire for adult Korean asthmatics (10).
Each question was answered by the patient on a 5-point scale,
with a score of 1 representing the greatest impairment and
a score 5 representing no impairment (lower AQLQ scores
therefore reflect increased impairment). Items were equally
weighted and reported as the mean score for each domain
(activity limitations, emotions, symptoms, and exposure to
environmental stimuli) along with an overall score.
Lung function tests
Baseline measurements of FVC and FEV1 were selected
according to American Thoracic Society criteria (8). Basal
and post-bronchodilator FEV1, FVC, and FEF25-75% were
measured. The measurement was made between 1 p.m. and
4 p.m. AHR was measured by a methacholine challenge test
and expressed as the provocation concentration to cause a fall
in FEV1 of 20% (PC20) in non-cumulative units (11). 
Sputum examination
Sputum was induced using isotonic saline containing a
short-acting bronchodilator as described by Norzila et al.
(12). Samples were treated within 2 hr of collection using the
method of Pizzichini et al. (13) with a minor modification.
Briefly, all visible portions with more solidity were carefully
selected and placed in a preweighed Eppendorf tube. Samples
were treated by adding four volumes of 0.1% dithiothreitol
(Sputolysin, Calbiochem Corp., San Diego, Calif., U.S.A.).
One volume of protease inhibitors (0.1 M EDTA and 2 mg/mL
*Plus-minus values are mean±SD. FEV1, forced expiratory volume in
one second. FVC, forced vital capacity; FEF, forced expiratory flow. 
� p<
0.01 compared with moderate asthma patients. AQLQ score, asthma
quality of life score.
Moderate asthma Severe asthma
Number 40 20
Age (yr) 46.2±14.7 42.2±13.4
Sex, male/female 23/17 11/19
FEV1, % predicted 70.5±4.8 51.5±5.4
�
FEV1/FVC 70.8±9.0 65.1±15.3
�
FEF25-75% 50.3±13.8 29.0±11.7
�
AQLQ 52.3±13.2 51.2±16.6
Atopy (%) 42.5 40
Duration of asthma (yr) 6.3±8.3 6.8±8.5
Pack years smoked 7.7±10.6 11.8±12.0
Blood eosinophils (%) 5.4±4.1 7.9±6.4
Sputum eosinophils (%) 4.3±11.3 8.0±14.9
Total IgE, Unit 350.2±616.1 634.2±496.7
Table 1. Baseline characteristics of the patients*588 J.-S. Choi, A.-S. Jang, J.-H. Lee, et al.
phenylmethylsulfonylfluoride) was added to 100 volumes of
the homogenized sputum, and the total cell count was deter-
mined with a hemocytometer. Homogenized sputum was
spun in a cytocentrifuge and 500 cells were read on each spu-
tum slide stained with Diff-quick solution (American Sci-
entific Products, Chicago, Ill., U.S.A.). 
Allegy skin prick tests
Allergy skin prick tests were performed using commercial-
ly available 55 inhalant allergens including dust mites (Der-
matophagoides farinae and Dermatophagoides pteronyssinus, Ben-
card co, Reinbek, Germany) and histamine (1 mg/mL, Ben-
card, U.K.). None of the subjects had received antihistamines
orally in the three days preceding the study. All tests includ-
ed positive (1 mg/mL histamine) and negative (diluent) con-
trols. After 15 min, the mean diameter of any wheal formed
by the allergen was compared with that formed by histamine.
If the former was the same or larger than the latter (A/H ratio
≥1.0), the reaction was deemed positive. Atopy was deter-
mined by the presence of an immediate skin reaction to one
or more aeroallergens as previously described (14). 
Statistical analysis
Data were doubled entered onto SPSS (v 10.0; SPSS Inc,
Chicago, IL, U.S.A.). Data are expressed as mean±SD. Com-
parison of continuous variables was made using independent
samples t testing. Differences in proportions were analyzed by
chi-square testing with Fisher exact test when low expected
cell counts were encountered. Pearson’s correlations and Spear-
man’s correlations were used to assess relationships between
variables. A p-value of <0.05 was considered significant.
RESULTS
The scores of AQLQ were significantly increased after 4
wks of inhaled GCs (overall; 51.9±14.3 vs. 67.5±12.1,
asthma symptoms; 13.5±4.5 vs. 18.4±4.2, limitation of
activity; 19.9±5.4 vs. 24.8±4.3, emotional functioning;
8.6±4.0 vs. 12.1±3.2, environmentally induced symptom;
10.0±3.6 vs. 12.1±2.4, respectively p<0.01. Fig. 1). Dur-
ing the study period, 33 patients (55.0%) with asthma showed
12% or more increase in FEV1 after high dose inhaled GCs
and 27 patients were non-responder. The change in FEV1
[ FEV1=(FEV1 at 4 wks-baseline FEV1)/baseline FEV1] fol-
lowing inhaled GCs was diverse from -21% to 126.8%. The
change in FVC [ FVC=(FVC at 4 wks-baseline FVC)/base-
line FVC] following inhaled GCs was diverse from -74% to
37%. The change in FEF [ FEF=(FEF at 4 wks-baseline
FEF)/baseline FEF] following inhaled GCs was diverse from
-27.0% to 100%. FEV1% predicted, FEF25-75%, FEV1/ FVC
were significantly increased at 4 wks of inhaled GCs in mod-
erate to severe asthmatics (Table 2). The responder of greater
than 12% in  FEV1 demonstrated significantly lower base-
*Plus-minus values are mean±SD. FEV1, forced expiratory volume in
one second. FVC, forced vital capacity; FEF, forced expiratory flow.
AQLQ score, asthma quality of life score.
Severe Moderate
(n=40) p (n=40) p
AQLQ 66.8±12.7 0.001 68.6±10.9 0.001
FEV1, % predicted 80.7±15.8 0.001 76.3±17.0 0.001
FEV1/FVC 74.4±11.9 0.0381 74.0±12.6 0.009
FEF25-75% 74.3±27.4 0.001 63.9±24.3 0.001
Table 2. Quality of life score, spirometry following inhaled glu-
cocorticoids for 4 wks compared with baseline value prior to
treatment
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Fig. 2. Change in overall AQLQ scores between responder and
non-responder after inhaled glucocorticoids for 4 wks.
p=0.001
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Fig. 1. The changes of AQLQ scores after inhaled glucocorticoids
for 4wks in moderate to severe patients with asthma. A; baseline,
B; 4 weeks, *p<0.05 compared with baseline values.
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line FEV1% predicted. The responder of greater than 12%
in FEV1 compared with non-responder had higher trend
proportion of sputum and blood eosinophils prior to treat-
ment (sputum; 6.17±12.0 vs. 4.90±8.52, blood 7.15±
5.18 vs. 4.88±3.72). Although the scores of AQLQ were
increased after 4 wks of inhaled GCs, there was no difference
of the scores of AQLQ at baseline and after treatment between
responder and non-responder (Fig. 2). Also there was no dif-
ference of the scores of AQLQ at baseline and after treatment
in terms of asthma severity and atopy. Duration of asthma,
age, sputum eosinophils, blood eosinophils, FEV1% predict-
ed at baseline, and PC20 methacholine were not correlated
with AQLQ. 
DISCUSSION
Quality of life scores and FEV1% predicted were improved
in patients with moderate to severe asthma after high dose
inhaled GCs, indicating that AQLQ as well as pulmonary
function test may be an additive clinical parameter for effec-
tiveness of GCs treatment in patients with asthma.  
Clinical trials in asthma have studied on physiological mea-
sures of outcome such as airway caliber (15) and responsive-
ness (16). Questionnaires on asthma symptoms and treatment
requirements have been used to assess clinical severity, but
they have tended to be restricted to conventional clinical symp-
toms and have not taken into the impact of the symptoms
and other aspects of the disease on the patients’ lives. Asthma
is associated with significant impairments of quality of life.
Specific quality of life scales include questions targeted to
asthma; many studies have been employed in clinical trials
(17-21).
GCs, usually administered by means of inhalation, are potent
inhibitors of inflammatory responses and therefore are current-
ly considered to be the standard therapeutic regimen for the
treatment of persistent asthma (22). GCs treatment of asth-
matic patient reduces the numbers of infiltrating eosinophils
and lymphocytes in the airways and decreases production and
release of pro-inflammatory mediators and cytokines. As a
consequence, some of the structural abnormalities of asthmat-
ic airways are normalized after GCs treatment (23). In our
study, responder asthmatic patients had higher trend of blood
and sputum eosinophils prior to inhaled GCs, indicating that
asthma patients with eosinophilic airway inflammation may
be more responsible to inhaled GCs. 
It is now well documented (24, 25), in both adults and
children, that long-term treatment with inhaled GCs sup-
presses the disease by affecting the underlying airway inflam-
mation. As a result, symptoms disappeared and lung function
improves. The outcome parameter responding most rapidly
to the initiation of inhaled steroid therapy is symptoms, PEF
values improve gradually, while improvements in AHR may
continue over many months or even years. Inhaled GCs may
also modify the disease outcome if prescribed early enough
and long enough. In this study we evaluated effect of high
dose inhaled GCs to exclude dose dependent effect of GCs.
We found that significant increase in FEV1 was observed at
4 wks in patients with asthma received high dose inhaled
GCs. The responsiveness to inhaled GCs was diverse among
patients with asthma. 
The scores of AQLQ were used as a tool to measure out-
come of drug treatment. Measurement of AQLQ may show
benefits of asthma treatments not revealed by objective moni-
toring and can complement clinical and physiological assess-
ments of treatment outcome (16, 20, 21, 26-29). In this study,
we found that the scores of AQLQ in terms of overall and each
item were improved after treatment of inhaled GCs, indi-
cating that the AQLQ is valuable as the conventional clini-
cal variables considered important in measuring asthma con-
trol. The correlations between pulmonary function and AQLQ
scores not observed in this study, which was in consistent with
Marks et al. (30). In contrast with Juniper et al. (27, 29) cor-
relations between severity and AQLQ scores not observed
due to the smaller sample size. Also age, atopy, duration of
asthma, PC20 methacholine was not correlated with AQLQ
scores. 
The scores of AQLQ in terms of overall and each item were
improved after treatment of GCs for 4wks, suggesting that
the AQLQ can be used as a measure of outcome in GCs respon-
siveness in asthma.
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